Financial Trends -- 5/10

Stable, not accelerating. Flat-to-low-single-digit revenue growth (+1.3% FY25, +4.9% 1Q26) with strong-but-volatile cash generation, expanding underlying margins (+460bps Non-GAAP GM over two years), and a shrinking share count -- offset by a 2025 debt build to fund M&A and large one-time IPR&D charges that distort GAAP/Non-GAAP profit in 2023Q2/Q4 and again in 2026Q1. The Gardasil-China collapse pushed revenue YoY negative in 1H25 before vaccine/oncology/Winrevair re-acceleration in 2H25; the Keytruda LOE (~2028) caps the durability narrative. FCF is positive every year but fell -32% in 2025 -- the one failed quality-gate criterion. Weight: 25%

1Q26 Revenue

$16.3B

src | +4.9% YoY | Re-accelerating

Margins

Expanding

+460bps 2yr Non-GAAP GM | Stalling YoY

FCF

Not Growing

Positive but FY25 -32% YoY | Gate NO

Share Count

Declining

2,547M to 2,472M | Buyback-driven

Quarterly Revenue Trajectory ($M)

Quarter	2Q24	3Q24	4Q24	1Q25	2Q25	3Q25	4Q25	1Q26
Total Revenue	$16,112M	$16,657M	$15,624M	$15,529M	$15,806M	$17,276M	$16,400M	$16,286M
YoY	+7.2%	+4.4%	+6.8%	-1.6%	-1.9%	+3.7%	+5.0%	+4.9%

Decelerated through 1H25, then re-accelerated -- directionally flat-to-modestly-positive, not a clean acceleration. The 1H25 dip (-1.6%, -1.9%) was the Gardasil-China shipment halt (HPV inventory destocking); the 2H25 re-acceleration was led by Keytruda, the Winrevair ramp, Animal Health, and Capvaxive. 1Q26 printed +4.9% YoY. This is a "stable" top-line profile, not the clean acceleration a top score requires.

Gross Profit & Margin -- the stall the multiple ignores ($M)

Metric	1Q25	1Q26	YoY
Gross Profit	$12,110M	$12,091M	-0.2%
Non-GAAP Gross Margin	82.2%	81.9%	-30 bps

Margin expansion has stalled on a YoY basis. The headline "+560bps from trough / +460bps over two years" is real, but the trend has flattened: 1Q26 Non-GAAP gross margin of 81.9% is -30bps vs 1Q25's 82.2%, and 4Q25 dipped to 79.7% on higher inventory reserves. Gross profit dollars were essentially flat YoY (-0.2%). The two-year margin story is a clear positive; the near-term trajectory is decelerating, not still expanding.

Annual Financial Summary (FY ends December)

Metric	FY2021	FY2022	FY2023	FY2024	FY2025
Total Revenue ($M)	$48,704M	$59,283M	$60,115M	$64,168M	$65,011M
Rev YoY	—	+21.7%	+1.4%	+6.7%	+1.3%
Non-GAAP Net Income ($M)	$15,282M	$19,005M	$3,837M*	$19,444M	$22,513M
Non-GAAP Gross Margin	—	—	76.9%	80.8%	81.5%
Diluted Shares (M)	2,538	2,542	2,547	2,541	2,507
Free Cash Flow ($M)	$8,674M	$14,707M	$9,143M	$18,096M	$12,360M
FCF YoY	—	+69.6%	-37.8%	+97.9%	-31.7%
Long-Term Debt ($M)	$30,690M	$28,745M	$33,683M	$34,462M	$46,750M

* FY2023 Non-GAAP net income depressed by the ~$10B Prometheus IPR&D charge -- one-time, not operational.

Key trends

Revenue decelerating in trend terms: the +21.7% in 2022 was the COVID/Lagevrio + Keytruda surge; ex-COVID the base business has grown low-single-digits (+1.4%, +6.7%, +1.3%)
Margins expanded +460bps Non-GAAP GM over two years (76.9% to 81.5%) on favorable oncology mix and lower COVID/Lagevrio drag -- but the expansion has stalled YoY into 1Q26
Share count declining: 2,547M (2023) to 2,507M (2025), continuing to 2,472M intra-2026 as buybacks step up -- no dilution
FCF positive but choppy and lower in 2025: $18.1B to $12.4B (-32%) on working capital and higher capex -- the failed gate criterion
Long-term debt jumped +36% in 2025 ($34.5B to $46.8B) to fund the M&A/licensing program, growing far faster than the +1.3% revenue (net debt/EBITDA ~2.3x)

FY2025 Revenue by Franchise ($M, Global)

Franchise / Segment	FY2025 Revenue	% of Total
Keytruda (oncology)	$31,641M	48.7%
Gardasil (HPV vaccines)	$5,233M	8.0%
Winrevair (PAH)	$1,443M	2.2%
Other Pharmaceutical	~$19,825M	~30.5%
Animal Health	$6,354M	9.8%
Pharmaceutical Segment Total	$58,142M	89.4%
Total Company	$65,011M	100%

Concentration is the core financial risk. Keytruda alone is ~49% of company revenue and faces its U.S. patent cliff in 2028. The Winrevair ramp and a diversifying launch portfolio are the offset, but no single asset replaces $31.6B.

Quarterly Free Cash Flow ($M)

Metric	1Q25	2Q25	3Q25	4Q25	1Q26
Operating CF	$2,500M	$3,293M	$7,822M	$2,857M	$3,918M
Capex (OCF less FCF)	($1,328M)	($764M)	($987M)	($1,033M)	($991M)
Free Cash Flow	$1,172M	$2,529M	$6,835M	$1,824M	$2,927M
FCF YoY	-47%	-48%	-20%	-27%	+150%

FCF positive but NOT growing -- the failed quality-gate criterion. FCF is solidly positive every quarter and every year (FY2025 $12.4B), but quarterly FCF YoY was negative for four straight quarters (1Q25-4Q25) on working capital and higher capex; full-year FY2025 FCF fell -32% ($18.1B to $12.4B). The +150% 1Q26 print is a low-base rebound, not a new growth trend. This is the single most important quality blemish.

Blemishes -- Distortions, Not Operational Deterioration

Blemish	Detail	Penalty
GAAP one-time charges	1Q26 GAAP operating income -$3.2B and Non-GAAP net income -$3.16B reflect a one-time ~$10B IPR&D charge (LaNova/Hengrui licensing) plus Keytruda litigation settlement. 2023Q2/Q4 hit by Prometheus IPR&D. Underlying 1Q26 revenue +4.9% and GM 81.9% remain healthy.	None
Debt build (+36% in 2025)	LT debt rose $34.5B to $46.8B to fund M&A/licensing, faster than +1.3% revenue. A 2-3 quarter deliberate build (net debt/EBITDA ~2.3x), not distressed leverage -- flagged, not penalized.	Flag only
FCF not growing	FY2025 FCF -32% YoY; four straight quarters of negative FCF YoY. Positive every period, so no negative-FCF penalty -- but it fails the "positive AND growing FCF" gate criterion.	Gate NO

Score Rationale

Score of 5/10 reflects solidly average financial trends -- the share-count tailwind and margin expansion roughly offset a decelerating top-line and a weaker 2025 FCF year.

Supports the midpoint:

Revenue roughly stable (flat-to-low-single-digit, decelerating trend but not collapsing): +1.3% FY25, +4.9% 1Q26
Non-GAAP gross margin expanded +460bps over two years (76.9% to 81.5%)
Share count declining on buybacks (2,547M to 2,472M) -- no dilution

What pulls it off the top path:

FCF positive but NOT accelerating -- FY2025 fell -32% YoY; quarterly FCF YoY negative for four straight quarters (the failed gate criterion)
Revenue trend decelerating ex-COVID; the Gardasil-China collapse drove 1H25 negative before re-acceleration
+36% debt build in 2025 to fund M&A, growing far faster than revenue (flagged, not penalized)
The looming 2028 Keytruda LOE caps the durability narrative

Penalty modifiers reviewed: negative FCF N/A (positive every year); dilution N/A (shares declining); revenue-up/op-income-down N/A on a clean basis (GAAP dips are one-time IPR&D); debt-outgrowing-revenue borderline (2-3 quarters, deliberate M&A) -- flagged, not penalized. Net: 5/10.

Quality gate -- positiveGrowingFcf: FCF is solidly positive but NOT growing (2025 FCF -32% YoY). Answer: no.

Data sourced from Daloopa. Fiscal year ends December 31. All financials in USD. FCF = operating cash flow less capex.